Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Safety, PK, and PD of CRN04894 in Healthy Volunteers
NCT06048887Phase 1Completed
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Dec 2020
- Primary completion
- Apr 2022
- Modality
- Allosteric Modulators, Orthosteric Ligands, Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of atumelnant in congenital adrenal hyperplasia (CAH), Cushing's disease (CD) and ectopic adrenocorticotropic hormone syndrome (EAS) (2 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Percentage of subjects with treatment-emergent adverse events and Proportion of participants with a clinically significant safety laboratory observation. Started Dec 2020; status: completed.
02
Drugs
atumelnant
03
Conditions
congenital adrenal hyperplasia (CAH)Cushing's disease (CD)ectopic adrenocorticotropic hormone syndrome (EAS)
Beyond the preview
Go deeper on NCT06048887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06048887.